In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without Helicobacter pylori eradication.
In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without Helicobacter pylori eradication. In addition, we will analyze the correlation between the incidence and survival rate of this type of stomach cancer by comparing smoking, gastric cancer direct family history, disease stage (TNM staging), the histologic type of stomach cancer (intestinal, diffuse, mixed), and the surgical method (Billoth I, Billoth II) as well as the infection and eradication status of H. pylori.
Study Type
OBSERVATIONAL
Enrollment
3,700
Antibiotic eradication therapy (triple or quadriple regimen)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Overall survival
Time frame: From date of initial curative surgery for gastric cancer, until the date of death from any cause, up to 60 months
Gastric cancer-specific (disease-free) survival
Survival period without cancer recurrence or newly developed stomach cancer diagnosis
Time frame: From date of initial curative surgery for gastric cancer, until the date of diagnosis of gastric cancer recurrence or the date of death, whichever comes first, up to 60 months
Metachronous cancer (remnant stomach cancer)
The number of patients who were diagnosed with new carcinoma on the remnant stomach, over follow-up period of up to 60 months, in eradication group and non-eradication group
Time frame: Up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.